Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics, Inc. announced that three abstracts featuring its investigational intravenous Deciparticle everolimus have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium scheduled for December 9-12 in San Antonio, Texas. The abstracts collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer. This development represents a significant step forward in addressing the limitations of current oral mTOR inhibitors like Afinitor, which suffer from poor bioavailability and restricted tumor penetration.

Deciparticle everolimus, designated as Sapu003, is a novel intravenous formulation developed by Sapu Nano, a joint venture between Oncotelic Therapeutics and Dragon Oversea. The formulation is specifically designed to overcome the pharmacokinetic challenges that have limited the effectiveness of traditional oral mTOR inhibitors in cancer treatment. By utilizing intravenous delivery, Sapu003 aims to achieve better drug distribution and enhanced tumor penetration, potentially leading to improved therapeutic outcomes for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

The acceptance of three separate abstracts at one of the most prestigious breast cancer conferences worldwide underscores the scientific community's interest in this innovative approach. The presentations will cover multiple aspects of the drug's development, including the underlying clinical rationale for targeting the mTOR pathway in this patient population, identification of relevant molecular biomarkers that may predict treatment response, and comprehensive pharmacokinetic data demonstrating the formulation's improved characteristics compared to existing oral alternatives.

For investors and stakeholders seeking additional information about Oncotelic Therapeutics, the company maintains a comprehensive newsroom available at https://ibn.fm/OTLC where updates and developments are regularly posted. The 2025 San Antonio Breast Cancer Symposium serves as a critical platform for presenting these findings to oncologists, researchers, and pharmaceutical industry professionals who specialize in breast cancer therapeutics. The symposium's acceptance of multiple abstracts on Sapu003 indicates recognition of the potential significance of this research within the oncology community.

This development comes at a time when the treatment landscape for metastatic breast cancer continues to evolve, with researchers seeking more effective and targeted therapeutic options. The mTOR pathway remains a validated target in hormone receptor-positive breast cancer, and improvements in drug delivery technology could potentially enhance the clinical benefits of mTOR inhibition while reducing side effects associated with current treatment regimens. The Phase 1 trial data to be presented will provide important insights into the safety profile and preliminary efficacy of this novel formulation in human subjects.